Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers

Leendert H. Zaaijer; Helena C. van Doorn; Marian J. E. Mourits; Marc van Beurden; Joanne A. de Hullu; Muriel A. Adank; Luc R. C. W. van Lonkhuijzen; Hans F. A. Vasen; Brigitte F. M. Slangen; Katja N. Gaarenstroom; Ronald P. Zweemer; Peggy M. L. H. Vencken; Caroline Seynaeve; Mieke Kriege

doi:10.1038/bjc.2016.333

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers

Leendert H. Zaaijer, Helena C. van Doorn, Marian J. E. Mourits, Marc van Beurden, Joanne A. de Hullu, Muriel A. Adank, Luc R. C. W. van Lonkhuijzen, Hans F. A. Vasen, Brigitte F. M. Slangen, Katja N. Gaarenstroom, Ronald P. Zweemer, Peggy M. L. H. Vencken, Caroline Seynaeve, Mieke Kriege^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: It is unknown whether a history of breast cancer (BC) affects the outcome of BRCA1/2-associated epithelial ovarian cancer (EOC). This was investigated in the current analysis. Methods: We included 386 BRCA1/2-associated EOC patients diagnosed between 1980 and 2015. Progression-free survival (PFS), progression-free interval (PFI), overall survival (OS) and ovarian cancer-specific survival (OCSS) were compared between EOC patients with and without previous BC. Results: BRCA-associated EOC patients with, vs without, a BC history had a significantly worse PFS and PFI (multivariate hazard ratio (HRmult) 1.47; 95% confidence interval (CI) 1.03-2.08 and HRmult 1.43; 95% CI 1.01-2.03), and a non-significantly worse OS (HRmult 1.15; 95% CI 0.84-1.57) and OCSS (HRmult 1.18; 95% CI 0.85-1.62). Ovarian cancer-specific survival was significantly worse for the subgroup treated with adjuvant chemotherapy for BC (HRmult 1.99; 95% CI 1.21-3.31). Conclusions: Our results suggest that BRCA1/2-associated EOC patients with a previous BC have a worse outcome than EOC patients without BC, especially when treated with adjuvant chemotherapy.

Original language	English
Pages (from-to)	1174-1178
Journal	British Journal of Cancer
Volume	115
Issue number	10
DOIs	https://doi.org/10.1038/bjc.2016.333
Publication status	Published - 8 Nov 2016

Keywords

BRCA mutation
breast cancer
ovarian cancer
survival
chemotherapy

Access to Document

10.1038/bjc.2016.333Licence: CC BY-NC-SA

Cite this

Zaaijer, L. H., van Doorn, H. C., Mourits, M. J. E., van Beurden, M., de Hullu, J. A., Adank, M. A., van Lonkhuijzen, L. R. C. W., Vasen, H. F. A., Slangen, B. F. M., Gaarenstroom, K. N., Zweemer, R. P., Vencken, P. M. L. H., Seynaeve, C., & Kriege, M. (2016). Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 115(10), 1174-1178. https://doi.org/10.1038/bjc.2016.333

@article{be874ed62ce04ebe9e05f21dd4cea170,

title = "Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers",

abstract = "Background: It is unknown whether a history of breast cancer (BC) affects the outcome of BRCA1/2-associated epithelial ovarian cancer (EOC). This was investigated in the current analysis. Methods: We included 386 BRCA1/2-associated EOC patients diagnosed between 1980 and 2015. Progression-free survival (PFS), progression-free interval (PFI), overall survival (OS) and ovarian cancer-specific survival (OCSS) were compared between EOC patients with and without previous BC. Results: BRCA-associated EOC patients with, vs without, a BC history had a significantly worse PFS and PFI (multivariate hazard ratio (HRmult) 1.47; 95% confidence interval (CI) 1.03-2.08 and HRmult 1.43; 95% CI 1.01-2.03), and a non-significantly worse OS (HRmult 1.15; 95% CI 0.84-1.57) and OCSS (HRmult 1.18; 95% CI 0.85-1.62). Ovarian cancer-specific survival was significantly worse for the subgroup treated with adjuvant chemotherapy for BC (HRmult 1.99; 95% CI 1.21-3.31). Conclusions: Our results suggest that BRCA1/2-associated EOC patients with a previous BC have a worse outcome than EOC patients without BC, especially when treated with adjuvant chemotherapy.",

keywords = "BRCA mutation, breast cancer, ovarian cancer, survival, chemotherapy",

author = "Zaaijer, {Leendert H.} and {van Doorn}, {Helena C.} and Mourits, {Marian J. E.} and {van Beurden}, Marc and {de Hullu}, {Joanne A.} and Adank, {Muriel A.} and {van Lonkhuijzen}, {Luc R. C. W.} and Vasen, {Hans F. A.} and Slangen, {Brigitte F. M.} and Gaarenstroom, {Katja N.} and Zweemer, {Ronald P.} and Vencken, {Peggy M. L. H.} and Caroline Seynaeve and Mieke Kriege",

year = "2016",

month = nov,

day = "8",

doi = "10.1038/bjc.2016.333",

language = "English",

volume = "115",

pages = "1174--1178",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "10",

}

Zaaijer, LH, van Doorn, HC, Mourits, MJE, van Beurden, M, de Hullu, JA, Adank, MA, van Lonkhuijzen, LRCW, Vasen, HFA, Slangen, BFM, Gaarenstroom, KN, Zweemer, RP, Vencken, PMLH, Seynaeve, C & Kriege, M 2016, 'Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers', British Journal of Cancer, vol. 115, no. 10, pp. 1174-1178. https://doi.org/10.1038/bjc.2016.333

TY - JOUR

T1 - Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers

AU - Zaaijer, Leendert H.

AU - van Doorn, Helena C.

AU - Mourits, Marian J. E.

AU - van Beurden, Marc

AU - de Hullu, Joanne A.

AU - Adank, Muriel A.

AU - van Lonkhuijzen, Luc R. C. W.

AU - Vasen, Hans F. A.

AU - Slangen, Brigitte F. M.

AU - Gaarenstroom, Katja N.

AU - Zweemer, Ronald P.

AU - Vencken, Peggy M. L. H.

AU - Seynaeve, Caroline

AU - Kriege, Mieke

PY - 2016/11/8

Y1 - 2016/11/8

N2 - Background: It is unknown whether a history of breast cancer (BC) affects the outcome of BRCA1/2-associated epithelial ovarian cancer (EOC). This was investigated in the current analysis. Methods: We included 386 BRCA1/2-associated EOC patients diagnosed between 1980 and 2015. Progression-free survival (PFS), progression-free interval (PFI), overall survival (OS) and ovarian cancer-specific survival (OCSS) were compared between EOC patients with and without previous BC. Results: BRCA-associated EOC patients with, vs without, a BC history had a significantly worse PFS and PFI (multivariate hazard ratio (HRmult) 1.47; 95% confidence interval (CI) 1.03-2.08 and HRmult 1.43; 95% CI 1.01-2.03), and a non-significantly worse OS (HRmult 1.15; 95% CI 0.84-1.57) and OCSS (HRmult 1.18; 95% CI 0.85-1.62). Ovarian cancer-specific survival was significantly worse for the subgroup treated with adjuvant chemotherapy for BC (HRmult 1.99; 95% CI 1.21-3.31). Conclusions: Our results suggest that BRCA1/2-associated EOC patients with a previous BC have a worse outcome than EOC patients without BC, especially when treated with adjuvant chemotherapy.

AB - Background: It is unknown whether a history of breast cancer (BC) affects the outcome of BRCA1/2-associated epithelial ovarian cancer (EOC). This was investigated in the current analysis. Methods: We included 386 BRCA1/2-associated EOC patients diagnosed between 1980 and 2015. Progression-free survival (PFS), progression-free interval (PFI), overall survival (OS) and ovarian cancer-specific survival (OCSS) were compared between EOC patients with and without previous BC. Results: BRCA-associated EOC patients with, vs without, a BC history had a significantly worse PFS and PFI (multivariate hazard ratio (HRmult) 1.47; 95% confidence interval (CI) 1.03-2.08 and HRmult 1.43; 95% CI 1.01-2.03), and a non-significantly worse OS (HRmult 1.15; 95% CI 0.84-1.57) and OCSS (HRmult 1.18; 95% CI 0.85-1.62). Ovarian cancer-specific survival was significantly worse for the subgroup treated with adjuvant chemotherapy for BC (HRmult 1.99; 95% CI 1.21-3.31). Conclusions: Our results suggest that BRCA1/2-associated EOC patients with a previous BC have a worse outcome than EOC patients without BC, especially when treated with adjuvant chemotherapy.

KW - BRCA mutation

KW - breast cancer

KW - ovarian cancer

KW - survival

KW - chemotherapy

U2 - 10.1038/bjc.2016.333

DO - 10.1038/bjc.2016.333

M3 - Article

C2 - 27755534

SN - 0007-0920

VL - 115

SP - 1174

EP - 1178

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 10

ER -